EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Analytic solution of a linear physiologically based pharmacokinetic model prototype useful in risk assessment



Analytic solution of a linear physiologically based pharmacokinetic model prototype useful in risk assessment



Biomarkers of human exposure to pesticides: developed from a symposium sponsored by the Division of Agrochemicals at the 204th national meeting of the American Chemical Society, Washington DC, 23-28 August 1992: 301-317



The use of analytic solutions of physiologically-based pharmacokinetic models to yield important qualitative and quantitative information about chemical exposure and risk in the human body is discussed.

(PDF emailed within 1 workday: $29.90)

Accession: 002301101

Download citation: RISBibTeXText



Related references

Symbolic solutions of small linear physiologically based pharmacokinetic models useful in risk assessment and experimental design. Biomarkers for agrochemicals and toxic substances: applications and risk assessment 255, 1996

Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough. Toxicological Sciences 126(1): 5-15, 2012

Evaluating a physiologically-based pharmacokinetic model for use in risk assessment. Toxicological Sciences 72(S-1): 182, March, 2003

Health risk assessment of tetrachloroethylene using a physiologically-based pharmacokinetic model. Abstracts of Papers American Chemical Society 207(1-2): ENVR 62, 1994

The implications of using a physiologically based pharmacokinetic model for pesticide risk assessment. Environmental Health Perspectives8: 1, 125-130, 2010

Development of a physiologically based pharmacokinetic model for risk assessment with 1 4 dioxine. Toxicology & Applied Pharmacology 105(1): 37-54, 1990

Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environmental Health Perspectives 108 Suppl 2: 283-305, 2000

The implications of using a physiologically based pharmacokinetic (PBPK) model for pesticide risk assessment. Environmental Health Perspectives 118(1): 125-130, 2010

Variability of physiologically based pharmacokinetic model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene. Toxicology Letters (Shannon) 68(1-2): 131-144, 1993

Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Toxicology Letters 79(1-3): 35-44, 1995

Physiologically based pharmacokinetic tissue compartment model selection in drug development and risk assessment. Journal of Pharmaceutical Sciences 101(1): 424-435, 2012

A computer program linking physiologically based pharmacokinetic model with cancer risk assessment for breast-fed infants. Computer Methods & Programs In Biomedicine. 46(2): 155-163, 1995

Incorporation of in vitro enzyme data into the physiologically-based pharmacokinetic (PB-PK) model for methylene chloride: implications for risk assessment. Toxicology Letters 43(1-3): 97-116, 1988

A physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment. Toxicology & Applied Pharmacology 114(2): 246-260, 1992